Table 2. Comparison of oxidative stress markers, inflammatory markers, vascular function measures, and endothelial progenitor cells after the clopidogrel and placebo treatment periods (n=41).

Characteristics	Clopidogrel (Mean ± SE)	Placebo (Mean ± SE)	p-value
Oxidative Stress Markers (Mean ± SE)
Cystine (μM)	105.25 ± 7.36	102.39 ± 7.29	0.71
Cysteine (μM)	13.71 ± 0.90	14.75 ± 0.89	0.39
Eh Cysteine/Cystine Ratio	-77.06 ± 1.76	-78.72 ± 1.74	0.73
Glutathione (μM)	1.52 ± 0.17	1.71 ± 0.17	0.28
Oxidized Glutathione (μM)	0.08 ± 0.06	0.19 ± 0.06	0.19
Eh Glutathione/Oxidized Glutathione Ratio	-130.62 ± 2.30	-128.47 ± 2.27	0.47
Inflammatory Markers (Mean ± SE)
Hs-CRP (mg/l)	5.98 ± 1.95	4.31 ± 1.95	0.55
CD40 Ligand (pg/ml)	1202.21 ± 318.35	2169.32 ± 318.35	0.03*
Vascular Function (Mean ± SE)
Flow-mediated vasodilation (%)	4.89 ± 0.59	4.81 ± 0.59	0.89
Nitroglycerin-mediated vasodilation (%)	19.31 ± 1.49	17.10 ± 1.51	0.17
Reactive Hyperemia Index	2.50 ± 0.80	2.20 ± 0.70	0.29
Augmentation Index at 75 beats per minute	25.04 ± 1.63	23.64 ± 1.62	0.26
Pulse Wave Velocity (m/s)	8.77 ± 0.45	9.044 ± 0.45	0.46
Endothelial Progenitor Cells (Mean ± SE)
CD34+ (cells/μl)	1.46 ± 0.16	1.54 ± 0.21	0.77
CD34+/CD133+ (cells/μl)	0.68 ± 0.07	0.75 ± 0.16	0.71
CD34+/VEGF2R+ (cells/μl)	0.08 ± 0.03	0.09 ± 0.02	0.70
CD34+/CD133+/VEGF2R+ (cells/μl)	0.03 ± 0.009	0.03± 0.008	0.96